

Chemotherapy Protocols

UROLOGICAL CANCERS

Protocol	Hospital using the Protocol
Bladder Cancer	
Accelerated MVAC	RSCH
Atezolizumab	RSCH
Gemcitabine & Carboplatin	RSCH
Gemcitabine & Cisplatin	RSCH
MMC, 5FU & Radiotherapy	RSCH
Paclitaxel & Carboplatin	RSCH
Paclitaxel & Gemcitabine	RSCH
Pembrolizumab (comp use)	RSCH
Prostate Cancer	
Abiraterone	RSCH, FPH
Cabazitaxel	RSCH
Cyclophosphamide oral	RSCH, SASH
Docetaxel	RSCH
E-Carbo-X	RSCH
Enzalutamide	RSCH
Mitoxantrone	RSCH, SASH
Renal Cell Carcinoma	
Axitinib	RSCH
Cabozantinib	RSCH
Everolimus (stored in Breast section)	RSCH
Interferon	RSCH
Nivolumab (stored in Skin section)	RSCH
Pazopanib	RSCH
Sunitinib	RSCH
Testicular Cancers	
3 day BEP	RSCH
5 day BEP (for intermediate risk tumours)	RSCH
Carboplatin	RSCH
EP	RSCH
IPE	RSCH
Penile Cancer	
Mitomycin, 5FU & RT (stored in anal cancer section)	RSCH

RSCH = Royal Surrey County Hospital; SASH = Surrey and Sussex Healthcare Trust

NB. The following reference sources were used routinely and are not individually referenced on each protocol:

Summary of Product Characteristics

Dose Adjustment for Cytotoxics in Renal and Hepatic Impairment, 2009 update,
produced by UCLH NHS Foundation Trust

“Main Toxicities” includes only predictable and/or important side effects. For more information on side effects not mentioned, please seek further literature.

For more information on fertility issues, see Appendices to protocols.

Reason for Update: Cabozantinib, Atezolizumab and Pembro (comp use) added; E-Carbo-F removed	Prepared by: S Taylor
Version: 18	Date: December 2017
Supersedes: Version 17	